Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics - sprookjes - yvandenbroek - TriplyDB

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

http://www.wikidata.org/entity/Q28179830

about

Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine Pediatric Statin Administration: Navigating a Frontier with Limited Data Genetic background of patients from a university medical center in Manhattan: implications for personalized medicine Membrane transporters in drug development Prediction of hepatic clearance in human from in vitro data for successful drug development.Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4).Xenobiotic, bile acid, and cholesterol transporters: function and regulation.Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants Synergistic interaction between genetics and disease on pravastatin disposition Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8)Several conserved positively charged amino acids in OATP1B1 are involved in binding or translocation of different substrates Adaptive hepatic and intestinal alterations in mice after deletion of NADPH-cytochrome P450 Oxidoreductase (Cpr) in hepatocytes Safety and efficacy of statins in Asians.Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing Impact of OATP transporters on pharmacokinetics.The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney.Genetic polymorphism of the human organic solute carrier protein 1 (hOSCP1) gene in Japanese patients with non-viral liver carcinoma.Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers.Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response Isolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae).Dyslipidemia in special ethnic populations Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide Pharmacogenetics-based new therapeutic concepts.SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients Transporters and their impact on drug disposition.Pharmacokinetic variability of anticancer agents.SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.Statin response and pharmacokinetics variants.

P2860

Q24676890-E1D52272-28EE-4619-A27D-AB15E0915701 Q26823434-6D6B4630-173B-4F4E-9BCE-5C552FD2568C Q27001267-82DD1355-511A-4962-B5F6-8B4915674C40 Q27692687-CC80DC3B-6D91-4BCD-8625-D4E205AB390E Q28068014-EE7AE462-E350-4A0C-95BD-90EBA40C7315 Q28478042-812CD25F-467D-41A9-A329-FE05CE590EC1 Q29616802-29814173-BB0E-4395-8BAA-32C8E3DD6059 Q33437736-699FFDF8-8263-40BD-ACEB-3E9DAF39E2E0 Q33673141-B5046424-237B-433B-8F26-BA4B0228AA67 Q33714593-011D2D82-700A-4C8F-8C0E-5D47E24A3C95 Q33776950-AFC005A2-B46E-46BC-8F1A-99CCF31A3C16 Q33786577-3854CB6F-14F5-4611-A37B-3B4932C176CD Q34042444-A134E667-887C-4385-A923-951B288BC725 Q34117674-FD46CD62-4819-46C8-8DE7-48791FAC1967 Q34340098-48F9E944-8F20-4E69-ABC2-7D047DDEEF5D Q34360031-54664F1D-D411-4993-A7BC-D489BE6BB957 Q34574500-C34C4A18-E4F7-4810-A4A6-FFEDC3440FAC Q34599850-873DDFA6-7B96-44D1-8FF2-79D6CD41A22D Q34608646-38D99A45-D3C8-45AC-8B43-C0F1DF02CCD8 Q34612244-55643303-7299-4B7C-80BA-CBF5CFC0CA84 Q34613443-B4B83B44-E4E8-48CF-B727-91B477A78764 Q34631971-47CFB617-1B32-49D9-B9BF-2E6F862FE072 Q34680467-690DD37C-5B8A-4376-8DE2-F820E041B754 Q34777362-929E36DD-9F32-44F4-BE61-5F69183417C4 Q34878913-339B042C-938D-4A95-90A2-A5C1B4E3E618 Q35080119-220073E5-CB57-4DE6-9A43-953F98F3E4A6 Q35088420-18C01E28-F8CC-4C9C-B694-B7AF85BEDFEF Q35135638-97ABA140-A6B4-4AE7-ACC2-FEE656C2A308 Q35297067-19EE6D21-46D3-4DA8-B888-161A7FC095FD Q35430039-465E6FED-7E0F-48F7-AE5B-7825ED2EAD05 Q35573543-A658745A-5780-4152-A772-65B143DEAC0A Q35607723-A60F3A18-8931-4B7C-AA72-EAEB22F6F66C Q35827696-3AA5C5E9-E2F3-4F8D-A713-39CFC9F77A44 Q35827882-C97CB610-A150-438F-A169-329A28F068FF Q35956177-27821441-AFF8-43ED-ADEF-B1D9F031248F Q36024636-C7DD0752-8C7D-44A5-8530-DBB348A3B748 Q36123304-DE14442D-D581-47E9-890D-B374863FD482 Q36146910-732D1597-D1B6-48FA-8464-62E94C454134 Q36184009-1123C644-7B27-416E-B79F-A5E94212BFD4 Q36192738-B83F2744-414B-4838-914C-6C7F0AA8F1F5

P2860

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

http://www.wikidata.org/entity/Q28179830

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Polymorphisms of OATP-C (SLC21 ...... r pravastatin pharmacokinetics

@ast

Polymorphisms of OATP-C (SLC21 ...... r pravastatin pharmacokinetics

@en

Polymorphisms of OATP-C (SLC21 ...... r pravastatin pharmacokinetics

@nl

type

label

Polymorphisms of OATP-C (SLC21 ...... r pravastatin pharmacokinetics

@ast

Polymorphisms of OATP-C (SLC21 ...... r pravastatin pharmacokinetics

@en

Polymorphisms of OATP-C (SLC21 ...... r pravastatin pharmacokinetics

@nl

prefLabel

Polymorphisms of OATP-C (SLC21 ...... r pravastatin pharmacokinetics

@ast

Polymorphisms of OATP-C (SLC21 ...... r pravastatin pharmacokinetics

@en

Polymorphisms of OATP-C (SLC21 ...... r pravastatin pharmacokinetics

@nl

P1433

Q28179830-16C59958-8095-4B65-9A4E-E205A7F144CB

P1476

Q28179830-43DD7764-269D-428A-8FF0-354A82E42F59

P2093

Q28179830-1136E241-8494-4208-A5AF-69A914C2886B

Q28179830-1A347B3E-B693-4F2F-8A22-06EC74D4DC06

Q28179830-1FAEDD6F-012E-43FE-8E4F-97D86C369E83

Q28179830-2D61E4FA-073E-4284-9520-146710B68BD6

Q28179830-3FF368AC-3F19-41B7-8624-65A3C535B8B9

Q28179830-4A7AD7AB-B436-4A9F-855A-6ADA204FC653

Q28179830-7407C8D7-7282-4271-B68B-31754A8434E0

Q28179830-BBF3DE1A-FAD7-4563-8DE7-0947821363B8

Q28179830-C850D2AC-134C-48DC-8486-80CAD0887DBA

Q28179830-DF9AC7D1-6E23-4DBB-B456-6DD38142DB9A

P304

Q28179830-38F3ADB9-C2C4-4511-8F52-988C5C7142F3

P31

Q28179830-7342B8BB-11B2-4136-AA74-FFAEDA75BDCA

P356

Q28179830-21D712EE-EB4F-43E1-AC1E-F4CE065F280D

P407

Q28179830-A85955B1-4FF5-45E9-97EC-01706613DB92

P433

Q28179830-2E780EE4-3030-4FD0-AACC-263DD2544518

P478

Q28179830-03A9F5E6-0B6C-478A-B112-1AE780710E18

P577

Q28179830-407EB7C1-507B-4CD7-80A4-593B578D67AE

P698

Q28179830-8EB76629-47C1-4C0F-91F7-16B61A1D88B9

P921

Q28179830-257641C2-4492-4854-AFFA-7CC6E002026B

P356

S0009-9236(03)00060-2

P1433

Clinical Pharmacology & Therapeutics

P1476

Polymorphisms of OATP-C (SLC21 ...... r pravastatin pharmacokinetics

@en

P2093

Akinori Urae

http://www.w3.org/2001/XMLSchema#string

Hiroshi Suzuki

http://www.w3.org/2001/XMLSchema#string

Hiroshi Takane

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Kusuhara

http://www.w3.org/2001/XMLSchema#string

Ichiro Ieiri

http://www.w3.org/2001/XMLSchema#string

Kenji Otsubo

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Kawabata

http://www.w3.org/2001/XMLSchema#string

Miyuki Kimura

http://www.w3.org/2001/XMLSchema#string

Shin Irie

http://www.w3.org/2001/XMLSchema#string

Shun Higuchi

http://www.w3.org/2001/XMLSchema#string

P304

554-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0009-9236(03)00060-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12811365

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics